Generic Name and Formulations:
Olopatadine (as HCl) 0.6% (665mcg/spray); aqueous nasal spray; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for PATANASE:
Seasonal allergic rhinitis.
2 sprays in each nostril twice daily.
<6yrs: not recommended. 6–11yrs: 1 spray in each nostril twice daily.
Other nasal diseases: not recommended. Avoid eyes. Monitor for nasal mucosal changes. Discontinue if nasal ulceration develops. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants.
Bitter taste, headache, epistaxis, throat pain, post-nasal drip, cough, UTIs, nasal ulceration, nasal septal perforation, somnolence; children also: upper respiratory tract infection, pyrexia, rash.
Nasal spray pump—30.5g (240 sprays)
Clinical Pain Advisor Articles
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Opioid-Free Analgesia Use for Postsurgical Pain Limited
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- No Added Value With Liposomal Bupivacaine Following TKA With Peripheral Nerve Block
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Opioid-Related Deaths Represent Significant Public Health Burden
- Addressing Confidentiality Concerns With Electronic Access to Pediatric Medical Records
- Opioid-Related Adverse Events Common After Invasive Procedures
- Diagnosis and Treatment of Migraine in Children Should Consider Atopy
- Led by AG Sessions, DOJ Declines to Defend ACA Against Federal Lawsuit